Immuron taking forward new therapy for fatty liver disease
This article was originally published in Scrip
The Australian firm Immuron is planning to submit by the end of this year a US IND to begin a multinational Phase IIb trial with a potential treatment for non-alcoholic steatohepatitis (NASH), with the aim of starting enrolment in the first half of 2012.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.